Despite a weak macro market, biotechs actually performed pretty well yesterday. That was a surprise albeit a pleasant one. Clearly biotech has its mojo back as three or four months ago, the sector would have been down 5% on a day like yesterday. I have been talking about reactions to earnings as a signal about […]
July 10 Biotech Update
It was clearly a bad day in the market and the sector. It is looking more and more likely that the long anticipated correction is here and the question now is how deep of a correction and how long will it last? I would not be surprised to see at least a 5% correction in […]
July 9 Biotech Update
The market was better today but this is not surprising that we get a breather after the two day sell off. The key is what happens in the afternoon and tomorrow. In other words, we cannot know if this is simply a dead cat bounce before more selling or the end of a quick downdraft. […]
July 8 Biotech Update
Again there is not a lot of news outside of a marginally raised offer for SHPG but clearly the market is selling off. Is this the long awaited correction that I have been talking about? Perhaps. I think we need to see how stocks react to earnings to get a real sense. If stocks are […]
Catalyst Watch – Vol. 2, Edition 22 (7/7/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates AEZS: I’m […]
July 7 Biotech Update
So a relatively weak day in the markets but really nothing much going on and it seems more like another day of the summer doldrums. I think the vast majority of days are going to be like this with some to the upside and some to the downside. At some point, there will be some […]
BMY – In The Inflection Point
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years high $57.49 in early March 2014, as investors were anticipating the anti PD-1 data coming at ASCO-2014 and with high expectations for BMY’s data of […]
July 3 Biotech Update
It seems like a very slow day in the market as not a lot of news outside of the macro data, which was positive. The sector seemed to drag a little this morning but I would certainly not read anything into the move today given the volume and the morning heading into an early close […]
July 2 Biotech Update
A tough end to USA soccer in the World Cup but another good morning for biotech stocks. I have some follow up discussion from earlier this week as there is not a ton of new news this morning. I suspect that will be the case as we get closer to the long weekend (but we, […]
CAR-T in the spotlight: Cellectis
Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to $185M in milestones per product plus royalties on sales. Additionally, Pfizer has acquired a 10% stake in Cellectis. Pfizer has exclusive rights to develop 15 […]
July 1 Biotech Update
It was a good morning in the sector with some positive news and momentum, although we seemed to have faded a little. As I have been saying for awhile, I think the sector has a good shot to hit new all-time highs as long as the macro environment does not turn bearish. I do not […]
June 30 Biotech Update- Back in the Saddle Again
Vacation is over and I am back to the grind (although I cannot really call what I do a grind as it is enjoyable). This is extra early today as I have a lot of catching up to do today and wanted to get some thoughts out there before I get caught up in other […]
RTRX – In a Consolidation Mode
Retrophin, Inc. (RTRX) –Nasdaq During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]
Catalyst Watch – Vol. 2, Edition 21 (6/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates MNKD: PDUFA […]
Catalyst Watch – Vol. 2, Edition 20 (6/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates No updates […]
June 20 Biotech Update
I am glad that I did not miss too much yesterday but it is usually the case that a day or week off does not dramatically change your perspective. It was another good morning for biotechs and I still believe that we are going to make a run at the all-time sector highs if the […]
June 18 Biotech Update
The sector (and market really) has been choppy since late yesterday morning. I would not read anything into these movements as it is a combination of low volume summer doldrums and the lack of any strong short term trend. As I have been saying for awhile, there will be a positive bias to trading for […]
June 17 Biotech Update
The sector continues to do well and if the broader market correction holds off we may be making a move to all-time highs but I would remain cautious. In any case, the sector seems healthy at this point despite heading into the summer doldrums and a seasonally weak period. 1. So the one name I […]
ASCO small caps: SNSS KPTI CYTR IMUC ZEL
Sunesis (SNSS) The company presented a poster of an MD Anderson-sponsored trial of its investigational drug voseroxin plus decitabine. There was intriguing data with regard to the response rates. 30 patients (pts) were evaluable for response; 13 (43%) achieved CR, 6 (20%) CRp, and 3 (10%) CRi, for an ORR of 81% with no evidence […]
June 16 Biotech Update- Good Data at EHA
A generally good start to the week for the sector with perhaps the good data out of EHA providing a nice early bump to sentiment. It seems to me that EHA was much more significant for small caps and biotech this year than ASCO despite getting a lot less play heading into the weekend. So […]
